Science

Science Summary
ONIT Study

OVERVIEW

EyePromise Science Summary

Since 2001, EyePromise has been passionate about prevention and dedicated to fighting AMD through science-based nutraceuticals. To date, more than 300 published studies exist on nutrition, macular pigment, and the impact on eye health.

Click Here to download our complete Science Summary.

AMD & Macular Pigments:

(Zeaxanthin and Lutein)

AREDS 2 Study

(Chew, MD. et. al.)

• The AREDS 1 formula plus Lutein & Zeaxanthin vs. AREDS 1 & beta-carotene:

– 18% reduction in the progression to advanced AMD

– 22% reduction in the risk of progression to neovascular AMD

• AREDS formula along with Lutein + Zeaxanthin vs. AREDS formula with no Lutein + Zeaxanthin:

– 10% additional reduction in the risk of progression to advanced AMD

– 11% reduction in the risk of progression to neovascular AMD

– 26% reduction to advanced AMD in the lowest quintile – the group with the lowest dietary intake of Lutein and Zeaxanthin, which is more representative of the general population

Improvement of Retinal Function in Early Age-Related Macular Degeneration After Lutein and Zeaxanthin Supplementation: A Randomized, Double-Masked, Placebo-Controlled Trial

(Ma et. al. – American Journal of Ophthalmology, October 2012, Peking University Eye Center, Beijing, China)

• 108 subjects with early AMD supplemented with 10mg Lutein, 10mg Lutein & 10mg Zeaxanthin, 20mg Lutein, or placebo plus 36 age matched controls. (144 subjects)

• Pre and post supplementation multi-focal ERG was measured in 6 concentric annular zones around the macula

• Increased MPOD related positively to increases in N1P1 response density in ring 1 and ring 2 with little effect in ring 3 thru 6

• Improvement of N1P1 response densities was positively associated with MPOD increase, suggesting a causative effect of MPOD on retinal function and health

• Early functional abnormalities of the central retina in the early AMD patients may be improved by Lutein and Zeaxanthin supplementation

• The 10mg Lutein/10mg dietary Zeaxanthin arm had the greatest ERG documented retinal function increase in ring 1.

For more Science Summaries, please download the EyePromise Science Summary.

Advances in Ophthalmology & Visual System 

Ocular Nutrition Impact on Tear Film Study (ONIT)

Volume 2 Issue 2 – 2015 Sean P Mulqueeny, Robert L Davis, William D Townsend, and Bruce H Koffler Mulqueeny Eye Centers, USA *Corresponding author: Sean P Mulqueeny, Mulqueeny Eye Centers, 612 N New Ballas Road, Saint Louis, MO 63141, Tel: 314-542-3600; Email: Received: January 27, 2015 | Published: March 26, 2015

Abstract

Purpose: To better understand the role of a proprietary dietary supplement formulated to contain Omega 3 and seven other anti-inflammatories plays in patients with established clinical findings consistent with dry eye disease. Secondarily, this evaluation will attempt to discover if any of the diagnostic markers are predictive to the therapeutic approach of omega 3 anti- inflammatory dietary supplements.

Design: Clinic-based, multi-center cohort study.

Methods: This eight-week feasibility study was to determine if subjects presenting with dry eye confirmed by diagnostic markers and symptoms responded to nutritional therapy via an oral nutritional supplement (EyePromise EZ Tears). Analyses were completed on a subgroup of subjects with 4 of 7 possible diagnostic criteria.

Results: A total of 67 patients were enrolled between 18-79 years of age inclusive. At the conclusion of the study, improvement from baseline was demonstrated in OSDI decreasing scores by 38%. Improved tear breakup time and phenol red thread scores were seen and was reduced conjunctival staining. There was also a decrease noted in lid inflammation. Osmolarity scores were variable and inconclusive.  

Conclusion: Supplementation with this Omega-3 anti-inflammatory product in dry eye showed significant improvement in OSDI, TBUT, conjunctival staining, lid inflammation, and phenol red thread, tear meniscus, and corneal staining scores. This decrease in patient symptoms could be an indication of decreasing ocular surface inflammation and possible stabilization of the lipid layer. The change from baseline for these signs appears to be rapid, as differences were shown as early as one-week post-supplementation.

ONIT Clinical Research Study – AOVS-02-00038